HK Stock Market Move | HASHKEY HLDGS (03887) rises more than 10% and intends to use no more than 100 million Hong Kong dollars for share repurchase.
HASHKEY HLDGS (03887) rose more than 10%, as of the time of publication, it rose by 9.78%, closing at 3.03 Hong Kong dollars, with a trading volume of 2.4444 million Hong Kong dollars.
HASHKEY Holdings (03887) surged more than 10%, and as of the time of writing, it had increased by 9.78% to 3.03 Hong Kong dollars, with a trading volume of 2.444 million Hong Kong dollars.
In terms of news, HASHKEY Holdings announced last night that the board of directors has resolved to use the company's own funds (excluding proceeds from global offerings) to repurchase shares in the market not exceeding 100 million Hong Kong dollars from the date of approval of the repurchase authorization until the end of the next annual general meeting of shareholders. The company believes that the share buyback can demonstrate confidence in the company's business outlook and prospects, and ultimately bring benefits to the company and create value for shareholders.
Related Articles

William Li: Chinese car companies are transitioning from single-point competition to system competition.

New stock news | Meedu once again submits application to the Hong Kong Stock Exchange to develop and provide comprehensive technology-driven marketing, sales, and operational support services.

New Stock News | Lanna Cheng submits again to the Hong Kong Stock Exchange, dedicated to the discovery, development, and commercialization of radiopharmaceuticals for cancer diagnosis and treatment.
William Li: Chinese car companies are transitioning from single-point competition to system competition.

New stock news | Meedu once again submits application to the Hong Kong Stock Exchange to develop and provide comprehensive technology-driven marketing, sales, and operational support services.

New Stock News | Lanna Cheng submits again to the Hong Kong Stock Exchange, dedicated to the discovery, development, and commercialization of radiopharmaceuticals for cancer diagnosis and treatment.

RECOMMEND





